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Bladder cancer (BC) is the fourth most common cancer in men and
the seventh most common cancer in women (Lynch et al, 1995). In
Europe and the USA transitional cell carcinoma (TCC) dominates
and accounts for 95% of all BC (Parker et al, 1996), making it the
12th leading cause of cancer death (Heney et al, 1983). Around
30% of urinary tract TCCs are found as multiple tumours at the
time of diagnosis (Kiemeney et al, 1993). Although 70% of newly
diagnosed bladder TCCs are superficial, i.e. the tumour is confined
to the lamina propria, the disease represents a major therapeutic
challenge and a continuous threat to the patients since the tumours
recur after transurethral resection of the primary in more than 70%
of the cases (Heney et al, 1983; Thompson et al, 1993). In addi-
tion, progression to more advanced stages and/or grades occurs in
16—25% of the cases (Prout et al, 1992).
Implicit in the clinical observations above are several questions
concerning the clonal origin of multifocal uroepithelial carcinomas
and the mechanisms that are responsible for the local as well as
distant dissemination of cancer cells (recurrences and metastases
respectively). Many investigators, perhaps motivated by the poly-
chronotopicity of BC and the dysplastic changes that are usually
found in the mucosa surrounding bladder tumours (Wolf et al,
1982), have drawn the conclusion that a field defect must be present
(Richie et al, 1989). According to this field disease theory, the entire
epithelium is tumour prone in the sense that multiple polyclonal
primary lesions are likely to emerge from it, either synchronously or
metachronously (Yao et al, 1994). The alternative, monoclonal view
presupposes a common clonal origin to all uroepithelial tumours,
even the multifocal ones, implying that these macroscopically
distinct lesions develop as the result of intraluminal seeding of
cancer cells shed from the original tumour. Support for the mono-
clonal hypothesis has come from analyses of X-chromosome inacti-
vation in the tumour cells of female patients (Sidransky et al, 1992).
Other molecular genetic studies, mainly relying on the precise iden-
tification of TP53 mutations as clonal markers in multifocal uro-
epithelial tumours (Habuchi et al, 1993; Chern et al, 1996; Xu et al,
1996), have provided evidence pointing in the same direction.
However, since the tumours investigated in these studies were rather
advanced as far as stage and grade are concerned, they do not neces-
sarily yield information about the early genetic events in disease
progression and dissemination. No corresponding cytogenetic study
has been performed, in spite of the fact that this technique is partic-
ularly well suited to assess the clonal nature of neoplasms (Heim,
1992). We therefore decided to examine multifocal uroepithelial
(mostly bladder) tumours using chromosome banding analysis after
short-term culturing of the tumour cells.
MATERIALS AND METHODS
Samples from a total of 21 macroscopically distinct uroepithelial
tumour lesions (12 primary bladder tumours, two primary ureteral
tumours, six recurrent bladder tumours and one recurrent tumour
located in the prostatic urethra) were obtained from a total of six
patients, all with multifocal disease.
Patient 1 was a 54-year-old man who was first seen because
of macroscopic haematuria. On cystoscopic examination, four
papillary bladder tumours were noted (BT1—BT4) (Figure 1). A
transurethral resection of the tumours was performed and a
specimen for cytogenetic analysis was obtained from each tumour.
Patient 2 was a 75-year-old woman who was admitted to hospital
with a tentative diagnosis of pericarditis. The patient had no
previous history of urological problems but, because an abdominal
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Figure 1 Schematic illustration of the anatomical distribution of the 27 multifocal primary and recurrent uroepithelial carcinomas from the six patients.
BT, bladder tumour; UT, ureteral tumour; RT, recurrent tumourultrasound examination indicated the presence of multiple bladder
tumours, he was transferred to the urology department for assess-
ment and further management. On cystoscopic examination, three
bladder tumours were found (BT5—BT7) (Figure 1), and a specimen
from each was obtained after transurethral resection of the tumours.
Patient 3 was a 77-year-old man who at initial presentation had
two multicentric uroepithelial tumours, one in the bladder (BT8)
and the other in the left distal ureter (UT1) (Figure 1). A sample
from the bladder tumour was obtained by transurethral resection,
whereas the ureteral tumour was removed by segmental ureteral
resection followed by ureter reimplantation.
Patient 4 was a 64-year-old man who had a total of five uroep-
ithelial tumours, four in the bladder (BT9—BT12) and one in the
upper right ureter (UT2) (Figure 1). Samples for cytogenetic analysis
were obtained after transvesical resection of the bladder tumours,
whereas the ureteral tumour was removed by nephroureterectomy.
Three months later, a cystoscopy control showed four new papillary
tumours in the bladder (RT1—RT4) (Figure 1). A specimen for cyto-
genetic analysis was obtained by transurethral resection of the
tumour (RT1) located in the bladder neck (Figure 1).
Patient 5 was a 75-year-old woman in whom a primary bladder
tumour (BT13) (Figure 1) was detected in July 1997 and recurrent
disease in October 1997. On each occasion, the tumours were
endoscopically removed without any adjuvant treatment. In
February 1998, the patient developed three multifocal recurrent
bladder tumours (RT5—RT7) (Figure 1). These were removed by
transurethral resection and a specimen from each was obtained for
cytogenetic analysis.
Patient 6 was a 74-year-old man with a history of bladder tumours
(BT14 and BT15) (Figure 1) since January 1993. In spite of surgical
treatment, by 1996 he had developed six recurrences. Adjuvant treat-
ment with bacille Calmette-Gu￿rin (BCG) was therefore added to the
surgical measures, and when this proved to be of limited effect,
intravesical epirubicine treatment was given. The patient neverthe-
less developed a recurrence in July 1997, and in March 1998, two
tumours in the bladder and one in the prostatic urethra (RT8—RT10)
were found (Figure 1). The tumours were endoscopically removed
and a specimen from each obtained for cytogenetic analysis.
In all cases, great care was taken to avoid contamination or
mixing when the macroscopically separate tumours were sampled
or removed. All specimens were sent in separate containers to the
cytogenetics laboratory. Similar care was taken during the histo-
logical examination of each tumour. Grading and staging were
done according to WHO (1973) criteria and the UICC (1978)
tumour-node-metastasis (TNM) classification system respectively.
All samples intended for cytogenetic analysis were processed
separately. Short-term culturing and cytogenetic analysis were
done as described by Fadl-Elmula et al (1998). In brief, the speci-
mens were disaggregated mechanically and enzymatically using
collagenase II. The resulting cells and cell clumps were washed
three times in RPMI-1640 medium, plated out in vitrogen-coated
flasks and fed a modified Dulbecco￿s modified Eagle￿s medium
(DMEM)—F12 (1:1) medium. All cultures were harvested within
10 days. Colcemid was added 3—4 h before harvesting and the
cells were detached by trypsinization. After hypotonic shock in
0.05 M potassium chloride, the cells were fixed three times in
methanol:acetic acid (3:1). G-banding was obtained with Wright￿s
stain. Between 25 and 100 metaphase cells were analysed for each
tumour. The clonality criteria and the karyotype descriptions were
according to the ISCN (1995) recommendation.
RESULTS
The clinical and cytogenetic findings are summarized in Table 1
and Figures 1—3. The attempt to establish short-term cultures was
successful in all but samples BT3 and BT4 from patient 1, which
were hence uninformative. The cultures from all other samples
revealed clonal chromosomal abnormalities. Apart from chromo-
some 15, all chromosomes were involved in numerical and/or
structural rearrangements at least once. The most consistent was
rearrangement of chromosome 9, leading to loss of all or parts of
9p and/or 9q in all examined tumours, followed by rearrangement
of chromosomes 1, 3, 7, 8 and 11 in three cases each. Rearrange-
ments of chromosome 17 resulting in loss of the short arm were
seen in cases 5 and 6, and in tumour BT7 from case 2. Except for
case 6, in which hypotetraploid clones were seen, all stemlines
were pseudo- or near-diploid; an additional duplicated hyper-
tetraploid clone was seen in the tumours from patient 4. In all
patients, the various tumours were cytogenetically identical or, at
least, clonally related, the cytogenetic differences being restricted
to one to three aberrations.
DISCUSSION
Because 70% of bladder carcinomas are superficial at diagnosis
(Thompson et al, 1993), surgical cure ought to be attainable in at
least these patients. The actual clinical course in BC is neverthe-
less remarkably heterogeneous, with as many as 60% of patients
with superficial disease having recurrence(s) after transurethral
resection of the primary tumour(s) (Fitzpatrick et al, 1986). Good
prognostic markers and a better understanding of the pathogenic
mechanisms behind local and distant disease spreading are there-
fore urgently needed. Such information might help design new
therapeutic strategies geared towards the prevention of tumour
recurrence specifically and, in general, a more aggressive
approach in progression-prone cases.
There are three mechanisms that have been implicated in the
frequent multicentricity and high recurrence rate characteristic of
BC (Schmitz-Dr￿ger et al, 1996): implantation of cancer cells shed
from the primary tumour, growth of new carcinoma(s) at remote
sites, and regrowth of an incompletely resected primary tumour.
Against the regrowth hypothesis speaks the fact that the new
tumour almost always appears at a site different from the primary
(Harris et al, 1992). In addition, biopsying of the scar area after
removal of the primary tumour has failed to demonstrate any post-
resection residual cancer, especially in cases with superficial
disease (Badalament et al, 1996). The consistent cytogenetic
monoclonality among macroscopically distinct lesions found in
our study therefore speaks strongly in favour of the shedding and
seeding hypothesis, since the simultaneous growth of multiple,
pathogenically independent tumours is well-right irreconcilable
with the observed monoclonality. This conclusion is in complete
agreement with the impressions left by previous findings obtained
by molecular genetic techniques (Sidransky et al, 1992; Habuchi et
al, 1993; Chern et al, 1996; Xu et al, 1996).
All examined tumours showed cytogenetic aberrations
involving the short and/or long arm of chromosome 9, and indeed
the importance of chromosome 9 rearrangement as an early,
presumably primary, event in BC tumorigenesis is widely accepted
(Miyao et al, 1993; Gibas et al, 1997). The ubiquity of chromo-
some 9 changes in our series may be contrasted with the absence
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Table 1 Clinical and cytogenetic data on 21 multifocal uroepithelial carcinomas
Case Sex/Age Tumour/Site Stage/Grade Karyotype
1 M/54 BT1/Bladder Ta/G2 47,X,-Y,del(2)(q21q31),t(3;5)(q27;q31),del(5)
(q11q13),+7,–9,+r,+mar[50]
BT2/Bladder T1/G2 46,X,-Y,del(2)(q21q31),t(3;5)(q27;q31),del(5)
(q11q13),+7,–9,der(9;13)(q10;q10),+13,+r[45]
2 F/75 BT5/Bladder Ta/G1–2 46,X,t(X;9)(p11;p11),del(1)(p11),+del(1)(p11),
del(7)(q11),i(8)(q10),add(9)(q12),der(11)t(7;11)
(q11;p15)del(11)(q12),der(13)t(1;13)(p11;p11),
del(13)(q13q22),–14[100]
BT6/Bladder Ta/G1–2 46,X,t(X;9)(p11;p11),del(1)(p11),+del(1)(p11),
del(7)(q11),i(8)(q10),add(9)(q12),der(11)t(7;11)
(q11;p15)del(11)(q12),der(13)t(1;13)(p11;p11),
del(13)(q13q22),–14[100]
BT7/Bladder T1/G3 46,X,t(X;9)(p11;p11),del(1)(p11),+del(1)(p11),
del(7)(q11),add(9)(q12),der(11)t(7;11)(q11;p15)
del(11)(q12),der(13)t(1;13)(p11;p11),–14[30]/
46,X,t(X;9)(p11;p11),del(1)(p11),del(1)(p11),
del(7)(q11),i(8)(q10),add(9)(q12),der(11)t(7;11)
(q11;p15)del(11)(q12),der(13)t(1;13)(p11;p11),
del(13)(q13q22),–14[40]/
46,X,t(X;9)(p11;p11),del(1)(p11),+del(1)(p11),
del(7)(q11),i(8)(q10),add(9)(q12),der(11)t(7;11)
(q11;p15)del(11)(q12),der(13)t(1;13)(p11;p11),
del(13)(q13q22),–14,del(17)(p11)[26]
3 M/77 UT1/Ureter Ta/G1–2 46,XY,+1,der(1;14)(q10;q10),del(3)(q27),
add(4)(q34),–9,+mar[30]
BT8/Bladder Ta/G1 45,XY,+1,der(1;14)(q10;q10),del(3)(q27),
add(4)(q34),–9[25]
4 M/64 UT2/Ureter T1/G2 48–50,XY,del(3)(p13p23),+8,add(8)(p11)´2,
add(9)(p11),del(11)(q13q21),i(11)(q10),add(14)
(q21),del(16)(q22),–18,add(20)(q11),
+3–4mar[cp27]/9–100,idemx2[cp10]/46,XY[35]
BT9/Bladder T1/G2 48–50,XY,del(3)(p13p23),+8,add(8)(p11)´2,
add(9)(p11),del(11)(q13q21),i(11)(q10),
del(16)(q22),–18,+19,+3–4mar[cp60]/96–100,
idemx2[cp20]/46,XY[25]
BT10/Bladder T1/G2 48–50,XY,del(3)(p13p23),+8,add(8)(p11)´2,
–9,del(11)(q13q21),i(11)(q10),der(18)t(1;18)
(q21;q21),+3–4mar[cp23]/96–100,
idemx2[cp9]/46,XY[15]
BT11/Bladder T1/G2 48–50,XY,del(3)(p13p23),+8,add(8)(p11)´2,
add(9)(p11),del(11)(q13q21),i(11)(q10),del(16)
(q22),–18,+3–4mar[cp37]/96–100,
idemx2[cp6]/46,XY[14]
BT12/Bladder T1/G2 48–50,XY,del(3)(p13p23),+8,add(8)(p11)´2,
add(9)(p11),del(11)(q13q21),i(11)(q10),add(14)
(q21),del(16)(q22),–18,+3–4mar[cp22]/96–100,
idemx2[cp11]/46,XY[24]
RT1/Bladder T1/G2 48–50,XY,del(3)(p13p23),+8,add(8)(p11)´2,
add(9)(p11),del(11)(q13q21),i(11)(q10),add(14)
(q21),del(16)(q22),–18,+3–4mar[cp44]/96–100,
idem´2[cp10]/46,XY[20]
5 75/F RT5/Bladder T1/G2 43,XX,–9,del(10)(q22q24),–11,der(12;17)
(q10;q10)[25]
RT6/Bladder T1/G2 43,XX,–9,del(10)(q22q24),–11,der(12;17)
(q10;q10)[25]
RT7/Bladder T1/G2 43,XX,–9,del(10)(q22q24),–11,der(12;17)
(q10;q10)[25]
6 74/M RT8/Bladder Ta/G2 88–93,XXYY,add(6)(p21),add(8)(p11),
del(8)(p22),–9,add(16)(p11),der(17)t(1;17)
(q12;p11),+mar[cp28]
RT9/Bladder Ta/G2 89–94,XXYY,add(6)(p21),add(8)(p11),
del(8)(p22),–9,add(16)(p11),der(17)t(1;17)
(q12;p11),–1+1–2mar[cp25]
RT10/Bladder Ta/G2 89–93,XXYY,add(6)(p21),add(8)(p11),
del(8)(p22),–9,add(16)(p11),der(17)t(1;17)
(q12;p11),+mar[cp30]of abnormalities affecting chromosome 17 in most of the tumours,
in spite of the fact that such changes, too, are common in bladder
carcinomas, especially in invasive poorly differentiated TCCs
(Fujimoto et al, 1992; Grossfeld et al, 1997). In our series,
rearrangements of chromosome 17 resulting in loss of the short
arm were seen in cases 2, 5 and 6. It is worthy of note, however,
that the del(17)(p11) of case 2 was present only in a subclone in
the high-grade (G3) lesion (BT7), whereas the two simultaneously
occurring low-grade lesions (BT5 and BT6) had no chromosome
17 aberrations. In cases 5 and 6, finally, the lesions, though super-
ficial and of low-grade (G2), were multiple and late recurrences.
Our findings thus are in full agreement with the view that alter-
ations of chromosome 9 play a ubiquitous role in the earliest
phases of BC tumorigenesis, whereas changes of chromosome 17
signal the transformation to more aggressive tumour behaviour.
The crucial gene-level changes behind these chromosomal
rearrangements remain uncertain although attractive candidates,
e.g. the TP53 tumour suppressor gene in 17p and the cyclin genes
in 9p (Miller et al, 1986; Williamson et al, 1995), have
commanded considerable interest and may be pivotal in the
tumorigenic process (Reznikoff et al, 1996).
In two of the patients (cases 3 and 4), bladder tumour(s) were asso-
ciated with a ureteral tumour. Since all the tumours in each case, irre-
spective of their sites, were cytogenetically related demonstrating
their common clonal origin, and since downstream rather than
upstream shedding of cancer cells is more likely, the ureteral tumour
should be considered the primary one. Epidemiological data are
consistent with this conclusion. The presence of an upper urinary tract
tumour is associated with a 75% probability of finding tumour(s) also
in the bladder, whereas the risk of developing a ureteral tumour
following the diagnosis of a bladder tumour is only 4% (Kakizoe et
al, 1980; Kenworthy et al, 1996). In addition to the downstream
passage of urine, the decreased expression level of E-cadherin by
shed cancer cells (Morton et al, 1995) combined with the fact that
mucosal inflammation facilitates their subsequent implantation
(Rosin et al, 1994), thus provide good explanation for the observed
distribution of secondary tumours in BC. The adjuvant use of intrav-
esical BCG is known to reduce the recurrence rate in BC as well as
the progression of the disease, mostly by limiting tumour cell motility
(Garden et al, 1992). Unfortunately, the attachment of shed tumour
cells is not affected by BCG, which may explain the failure of this
approach in 20% of the patients (Unyime et al, 1994; Nicol, 1995).
10 I Fadl-Elmula et al
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Figure 2 Partial karyograms from cases 1, 5 and 6. BT, bladder tumour; RT, recurrent tumour. The chromosome indicated by ‘mar’ represents unidentified
marker, and ‘r’ represents ring chromosomes. Arrowheads indicate breakpointsAnother angle to the present study was to see whether recurrent
bladder tumours have the same genetic alterations as do primary
ones. The recurrent tumour of case 4 (RT1) developed 3 months
after the multiple primary tumours had been removed and at a
different site, and yet its karyotype was identical to that of BT12.
The absence of additional secondary chromosome abnormalities in
the recurrent tumour indicates that the seeding occurred after the
clonal evolution had taken place in BT12. In cases 5 and 6, we do
not know the karyotype of the original tumour, but again the
karyotypic similarity among the multiple recurrent tumours in
each case argues strongly for a single-cell origin. Similar to what
was seen in the multiple primary tumours, the cytogenetic findings
in recurrent BC indicate that the tumorigenic process is mono-
clonal. A similar conclusion has previously been reached based on
the immunohistochemical study of tumour suppressor gene
expression in recurrent bladder tumours (Chern et al, 1996). The
available cytogenetic information allows no conclusion as to
whether tumour cell shedding with subsequent implantation and
growth is more likely to occur from the first or later (second)
primary tumours, but judging from the clinical and epidemiolog-
ical data, both situations are common (Breul et al, 1992; Herr et al,
1997).
In spite of the growing understanding of the key role played by
tumour cell shedding in the development of second primary
bladder carcinomas, other elements in multifocal uroepithelial
tumorigenesis remain poorly understood. Sidransky et al (1992)
suggested a pathogenetic model based on early intraluminal
dissemination of transformed cells followed by the independent
growth of each cell, eventually resulting in multiple, clonally
related tumours that vary in their pattern of secondarily acquired
genetic alterations. Our findings seem to require a certain modifi-
cation of this view. The extensive cytogenetic similarity observed
among all tumours from the same patient, each tumour sharing 5—8
numerical and/or structural chromosome aberrations, suggests, in
addition to the common clonal origin, that seeding is a rather late
event; such similarity is hardly compatible with an early splitting
up of the monoclonal, neoplastic cell population followed by the
acquisition of secondary genetic changes.
That intraluminal shedding and implantation of tumour cells is
the mechanism responsible for both synchronous and metachro-
nous multifocal BC may be of considerable relevance for thera-
peutic strategies. Complete endoscopic removal of the primary
tumour is often not enough even in the treatment of superficial BC.
Additional measures should be directed toward stopping tumour
cell seeding and the ability of already implanted tumour cells to
divide. This implies more emphasis on intravesical adjuvant
therapy in superficial BC, including the use of anti-inflammatory
drugs, antagonists of cell adhesion and intravesical chemotherapy
Monoclonality in multifocal uroepithelial carcinomas 11
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or immunotherapy with BCG. The rationale for avoiding unneces-
sary trauma to the urothelium during the endoscopic removal of
bladder tumours also seems stronger. The practice of taking
random bladder biopsies or removing a benign prostate at the time
of bladder tumour surgery seems illogical in this perspective and
should probably be discontinued.
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